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Introduction 
Topical corticosteroids are ubiquitous in the 
treatment of various dermatoses [1]. Vehicles 
available for topical corticosteroids include creams, 
ointments, gels, lotions, solutions, and sprays. 
Although ointments, creams, and gels are often 
prescribed, an increasing use of nontraditional 
vehicles, including sprays and foams, are being 
prescribed for psoriasis and other inflammatory 
dermatoses. Since patients have specific priorities for 
topical vehicles, healthcare providers could explore 
patient preference for medication vehicles [2, 3].   
Patients may find topical sprays appealing since they 
are less messy, easy to apply, and leave minimal 
residue. A study investigating the trending use of 
sunscreen vehicles reported an increased use of 
sunscreen sprays and a decreased use of sunscreen 
lotions because consumers felt that sunscreen sprays 
were quick and easy to apply [4]. Multiple factors 
may influence a patient’s choice of vehicle but 
preference varies widely. Individualizing treatment 
may optimize adherence [1, 5]. 
Owing to an increasing popularity of nontraditional 
vehicles like sprays for topical therapy, this article will 
review available topical corticosteroid sprays and 
their efficacy and safety in treating certain 
inflammatory skin conditions [3, 4]. 
Clobetasol propionate 0.05% spray 
Clobetasol propionate 0.05% spray is a class 1, super-
potent topical corticosteroid used for the treatment 
of moderate-to-severe plaque psoriasis. Clobetasol 
proprionate 0.05% spray is FDA-approved for a 4-
Abstract 
Background: Topical corticosteroids are available in 
many vehicles. However, patients’ preference for 
vehicles are variable and could be tailored to 
maximize patient adherence. Spray vehicles may 
offer, convenience, and strong efficacy. 
Methods: A literature review was conducted using 
keywords: clobetasol, desoximetasone, 
betamethasone, triamcinolone, corticosteroid, 
topical, spray, vehicles, treatment, and clinical trial. 
Results: For moderate-to-severe plaque psoriasis, 
87% of subjects achieved an Overall Disease Severity 
(ODS) Score ≤2 at week two and 78% achieved an 
ODS ≤1 after four weeks with clobetasol propionate 
(CP) 0.05% spray compared to 17% and 3% in the 
control group, respectively (P<0.001). For 
desoximetasone 0.25% spray, 31%-53% with 
moderate-to-severe psoriasis achieve Physician’s 
Global Assessment (PGA) score ≤1 at day 28 versus 
5%-18% in the vehicle spray group (P<0.01). For 
betamethasone dipropionate 0.05% spray, 19% with 
mild-to-moderate plaque psoriasis achieved an 
Investigator’s Global Assessment (IGA) score ≤1 or a 
2-grade reduction in IGA versus 2.3% in vehicle group 
(P≤0.001). For mild-to-severe steroid responsive 
inflammatory dermatoses, 64% using triamcinolone 
acetonide 0.2% spray achieved clear or almost clear 
skin at day 14 (no P value reported). Adverse events 
including burning, irritation, and dryness were similar 
across all corticosteroids. 
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week, twice daily application in patients 18 years or 
older [6]. Total dose should not exceed 50g of 
product per week (59ml or two fluid ounces) to 
prevent HPA-axis suppression [6]. 
Efficacy 
A multicenter, randomized, double-blind, vehicle-
controlled, parallel-group, comparative study 
evaluated the efficacy of clobetasol propionate 
0.05% spray in 120 adults with moderate-to-severe 
plaque psoriasis affecting at least 2% of their body 
surface area. A successful primary outcome was 
defined as Overall Disease Severity (ODS) score of ≤2 
(mild, almost clear or clear) at week 2 and ODS score 
≤1 (clear or almost clear) at week 4. Secondary 
outcomes included reduction in disease severity for 
psoriasis signs and symptoms (scaling, erythema, 
plaque elevation and pruritus) at weeks 1 and 8 and 
calculated treatment success (defined as clear or 
almost clear) at week 8. Disease severity for psoriasis 
signs and symptoms were scored on a 5-point scale 
(0=none, 1=almost clear, 2=mild, 3=moderate, 
4=severe, 5=very severe). Subjects were randomized 
in a 1:1 ratio to receive clobetasol propionate 0.05% 
spray or vehicle. Subjects were instructed to apply 
the study medication twice daily for 4 weeks. 
Evaluations were conducted at baseline, weeks 1, 2, 
4, and 8. Superior results were achieved with 
clobetasol propionate 0.05% spray for both primary 
and secondary outcomes (Table 1). A significant 
amount of subjects in the clobetasol group 
maintained treatment success 4 weeks post-
treatment [7]. 
A 4-week open-label observational study 
investigated the efficacy of clobetasol propionate 
0.05% spray in subjects with psoriasis affecting 3% to 
20% of their body surface area. Effectiveness was 
measured using a 7-point Investigators’ Global 
Assessment of Improvement (GAI) scale 
(0=completely clear, 6=worsened) and a 6-point 
Target Plaque Severity (TPS) scale (0=clear, 5= very 
severe). Treatment success was defined as a score of 
0 or 1 on GAI or on TPS or an improvement of 2 
grades or more on TPS. Subjects were randomized to 
a monotherapy arm (N=1254) or add-on therapy arm 
(N=731) with another antipsoriatic agent in addition 
to clobetasol propionate 0.05% spray [8, 9]. Subjects 
in the add-on therapy arm had to have at least one 
target plaque with TPS score of moderate to severe. 
When clobetasol propionate spray was used as 
topical monotherapy, significant improvement from 
baseline was achieved in target plaque severity and 
overall severity after 2 weeks of treatment. After 4 
weeks of treatment, 80% of subjects achieved 
treatment success using topical monotherapy with 
clobetasol propionate 0.05% spray. Only 2% of 
subjects did not report grade improvement [8]. 
Clobetasol propionate 0.05% spray was also effective 
as additional topical therapy for patients already 
receiving topical or systemic antipsoriatic agent [9]. 
About 80% of subjects with a moderate-to-severe 
plaque achieved complete or almost complete 
clearing at 4 weeks when clobetasol propionate 
0.05% spray was used as adjunctive therapy [9]. 
A multicenter, randomized, clinical trial of 122 
subjects with moderate-to-severe plaque psoriasis 
affecting 3 to 20% of body surface area compared 
efficacy and safety of clobetasol propionate 0.05% 
spray to calcipotriene 0.005% mixed with 
betamethasone dipropionate 0.064% (C-BD) 
ointment. Subjects were instructed to apply 
medication twice daily and assessed at week 1, 2, 4 
and 8 (4 weeks post-treatment). A successful primary 
outcome was defined as an ODS score of ≤1 and IGA 
scale. Clobetasol propionate 0.05% spray efficacy 
was greater than C-BD ointment with 75% of 
subjects achieving clear or almost clear skin (ODS ≤1) 
after 4 weeks of treatment compared with 45% using 
C-BD ointment. Both clobetasol propionate 0.05% 
spray and C-BD ointment improved patient quality of 
life without any significant differences between both 
groups. Compared with C-BD ointment, subjects 
found clobetasol propionate 0.05% spray easier to 
apply and were more satisfied with their results [10]. 
A multicenter, double-blind clinical study 
randomized 81 subjects with moderate-to-severe 
scalp psoriasis to a clobetasol propionate 0.05% 
spray or vehicle spray applied twice daily. The 
primary efficacy outcome was measured using the 
Global Severity Score (GSS) for scalp psoriasis at week 
4. Subjects who achieved a score of 0 at week 2 were 
considered a treatment success and prematurely 
completed the study. End of treatment was therefore  
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either at week 2 or 4, depending on GSS score. 
Secondary end points included GSS at week 2, 
psoriasis individual sign scores, extent of scalp 
involvement index, and pruritus at weeks 2 and 4. 
Additional assessment included Scalpdex (a 
validated scalp dermatitis-specific quality of life 
instrument) score. Psoriasis individual sign scores 
rated scaling, erythema, and plaque elevation on a 4-
point scale. Extent of scalp involvement index was 
rated on a 5-point scale (0=none, 1= <20%, 2=20-
39%, 3=40-59%, 4=60-79% and 5=80-100%). Pruritus 
was evaluated on a 3-point scale (0=no itching, 
1=some itching, not bothersome, 2=definite itch, 
bothersome and 3=intense itching). At week 2, 12% 
of subjects achieved treatment success (GSS=0) in 
the clobetasol group compared with 0% in the 
placebo group whereas 68% of subjects in the 
intent-to-treat (ITT) group were almost clear 
compared with 8% in the placebo group. At the end 
of the study, 85% achieved treatment success (GSS 0 
[clear] or 1 [almost clear] at week 4 or GSS=0 at week 
2) in the clobetasol group compared with 13% in the 
placebo group (P<0.001), [11]. Over 90% of subjects 
experienced significant reductions in scaling, 
erythema, and plaque elevation in the ITT group 
compared with 31% to 48% in the vehicle spray 
group. For extent of scalp involvement index, 51% of 
subject in the clobetasol group reported 0% 
involvement versus 3% in the vehicle spray group at 
the end of the study (P<0.001). About 28% of 
subjects in the vehicle spray group had ≥40% 
involvement compared with 0% in the ITT group. 
Pruritus severity scores were significantly improved 
for subjects in the ITT group at end of treatment with 
97% of subjects rated as mild or no pruritus. Scalpdex 
scores improved by 25 points at end of treatment in 
the ITT group (P<0.001 versus baseline and vehicle 
spray). Both groups agreed or strongly agreed that a 
topical spray pump made scalp application easier 
(85% in clobetasol group; 86% in placebo group), 
[11]. 
Safety and Tolerability 
About 23% of CP 0.05% spray subjects reported 
application-site stinging/burning within 15 minutes 
following the first application. However, the placebo 
group also reported application-site 
stinging/burning suggesting the alcohol content 
may be attributed to the spray vehicle [7]. The most 
common adverse events reported were pruritus, 
moderate erythema, peeling/scaling, dryness, and 
stinging/burning. Telangiectasia, skin atrophy, and 
folliculitis were reported in 1% of subjects [7-9]. Scalp 
psoriasis subjects treated with CP 0.05% spray 
reported burning/stinging (26%) and telangiectasia 
(3%) [11]. 
Desoximetasone 0.25% spray 
Desoximetasone 0.25% spray is a potent to super-
potent topical corticosteroid [12]. Treatment 
indication includes adults with moderate-to-severe 
plaque psoriasis and atopic dermatitis. It can be used 
up to 4 weeks and should be applied directly to the 
affected site and rubbed in gently and completely 
[13]. It can provide rapid relief of scaling from 
psoriasis in up to 70% of patients in 1 week and 84% 
in 4 weeks [8]. Desoximetasone 0.25% spray has a 
low potential for irritation and sensitization and is 
less irritating than clobetasol spray [14]. 
Efficacy 
Two phase III, double-blind, vehicle-controlled 
parallel studies randomized 120 adult subjects with 
moderate-to-severe plaque psoriasis to 
desoximetasone 0.25% spray (active group) or 
vehicle applied twice daily for 28 days. At baseline, 
subjects required PGA of 3 (moderate) or 4 (severe) 
and a target lesion with an area of at least 5cm2 with 
a combined Target Lesion Severity Score (TLSS) of ≥7, 
and a plaque elevation score of ≥3. The primary 
endpoint included clinical success rate of PGA score 
0 or 1 at day 28, and treatment success was defined 
as TLSS of 0 or 1 for each of three individual signs 
(erythema, scaling, and plaque elevation) at day 28. 
Secondary efficacy endpoint was the mean change 
from baseline to day 28 in PGA, TLSS, and mean 
change in percent of body surface area affected. 
Subjects were instructed to apply study medication 
twice-daily directly to affected areas, then evaluated 
at day 7, 14, and 28. Overall improvement of psoriasis 
(measured by PGA) in the active groups was noted in 
31% to 53% of subjects compared with 5% to 18% in 
vehicle group (Study 1 P=0.0003; Study 2 P<0.0001). 
About 39% to 53% experienced complete or almost 
complete clearing of target plaques compared with 
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vehicle spray (P<0.0001). Mean changes from 
baseline in TLSS, PGA and BSA were statistically 
significant and in favor of desoximetasone 0.25% 
spray after 28 days of treatment [15]. 
A multicenter, double-blind clinical trial randomized 
120 adult subjects with moderate-to-severe plaque 
psoriasis to desoximetasone 0.25% spray or vehicle 
applied twice daily for 28 days. All participants had a 
baseline PGA of ≥3 and stable plaque psoriasis 
involving ≥10% of body surface area. Target plaques 
required an area of ≥5cm2, TLSS of ≥7 and plaque 
elevation >3. Subjects were assessed at baseline, day 
7, 14, and 28 using PGA score and TLSS. Primary 
outcome was the proportion of subjects that 
achieved clinical success, defined as PGA <1 at day 
28, and/or treatment success, defined as TLSS of ≤1 
for erythema, scaling, and plaque elevation at day 28. 
More subjects achieved PGA ≤1 at day 28 with 
desoximetasone 0.25% spray than vehicle spray 
(31% versus 5%, P=0.0003). More subjects achieved 
TLSS≤1 at day 28 with desoximetasone 0.25% spray 
than vehicle spray (39% versus 7%, P<0.0001), [16]. 
An open-label study evaluated the efficacy of 
desoximetasone 0.25% spray in 15 subjects with 
atopic dermatitis. All subjects were instructed to 
apply the medication twice daily, followed by a 
treatment evaluation at week 1, 2, and 4 using the 
IGA score. Primary outcome was a reduction in IGA 
score, and pruritus from baseline and mean 
reduction on Visual Analogue Scale (VAS) of pruritus 
from baseline. At baseline all subjects had an IGA 
score of moderate. A significant reduction in IGA 
scores was noted at week 1, 2, and 4 with all subjects 
rated as clear or almost clear at week 4 (P≤0.001). For 
pruritus, all subjects enrolled with a baseline score of 
moderate and at week 2, 13% persisted with a score 
of moderate with the remaining subjects rated as 
mild (54%) and no pruritus (33%), (P<0.002). At week 
4, all subjects reported either mild (40%) or no 
pruritus (60%), (P<0.002). Mean VAS percent change 
from baseline was -56%, -74% and -91% at week 1, 2, 
and 4, respectively (P≤ 0.0007), [17]. 
Safety and Tolerability 
Desoximetasone is a class C corticosteroid, which has 
the lowest potential for causing cutaneous allergies 
[18]. In both phase III trials, 28.3% and 15% of 
subjects reported adverse events in the active arms 
of Study 1 and 2, respectively [15]. A similar number 
of adverse events were reported in both vehicle 
control groups (35% Study 1; 20% Study 2), [15]. 
There was no difference between both study arms 
(no P value reported), [15]. Adverse events included 
application-site reactions such as dryness, irritation, 
pruritus, erythema, and rash [15]. No stinging or 
burning was reported by any subject [15]. Less than 
1% of subjects reported psoriasis exacerbation, 
folliculitis, and skin ulcers. No serious adverse events 
were reported [15]. About 69 adverse events (34, 
placebo group; 35, treatment group [no P value 
reported]) were reported in the multicenter, double-
blind trial [16]. No skin atrophy, specific, or serious 
adverse events were reported (no P value reported), 
[16]. Although sample size was small (N=15), no 
adverse events were reported for subjects with 
atopic dermatitis [17]. 
Betamethasone dipropionate 0.05% spray 
Betamethasone dipropionate 0.05% spray is a mid-
potency topical corticosteroid [19]. Its spray 
formulation is used for the treatment of mild-to-
moderate adult plaque psoriasis. Betamethasone 
dipropionate spray should be applied and rubbed 
gently to affected areas twice daily for 4 weeks [20]. 
Betamethasone dipropionate 0.05% spray has less 
systemic absorption than betamethasone 
dipropionate 0.05% lotion [19]. 
Efficacy 
A phase III, double-blind, vehicle-controlled trial 
randomized 394 subjects with mild-to-moderate 
plaque psoriasis affecting 10 to 20% body surface 
area to either betamethasone dipropionate 0.05% 
spray (N=174), betamethasone dipropionate 0.05% 
lotion (N=90), vehicle spray (N=87), or vehicle lotion 
(N=43). Subjects required baseline IGA of 3 
(moderate) and a diagnosis of stable plaque psoriasis 
not affecting the scalp, groin, axillae, or 
intertriginous region. Primary endpoint was defined 
as the proportion of subjects that achieve at least a 
two-grade reduction or rated clear or almost clear 
using the IGA scale at day 15 from baseline. 
Secondary outcomes were measured using the Total 
Sign Score (TSS, the sum of individual scored for 
erythema, scaling, and plaque elevation) for target  
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lesions. Subjects were evaluated at days 1, 4, 8, 15, 
and 29. More subjects achieved IGA ≤1 or a 2-grade 
reduction at day 15 with betamethasone 
dipropionate 0.05% spray than vehicle spray (19% 
versus 2.3%, P0.001). For betamethasone 
dipropionate lotion, 18.9% achieved an IGA ≤1 or a 
2-grade reduction at day 15 compared with 9.3% in 
the vehicle lotion group. More subjects had a 50% 
reduction in TSS with betamethasone dipropionate 
0.05% spray than vehicle spray at day 4 (12.1% versus 
2.3%, P=0.004). There was no TSS reduction 
difference between treatment groups at day 8, 15, 
and 29 (no P value reported), [19]. 
Safety and Tolerability 
Application-site adverse events for topical 
betamethasone dipropionate 0.05% spray included 
pain (18%), pruritus (15%), and atrophy (2.3%). No 
severe adverse events were reported in the 
betamethasone dipropionate spray group. 
Hypothalamus-pituitary-adrenal axis suppression 
was assessed for augmented betamethasone 
dipropionate 0.05% lotion versus betamethasone 
dipropionate 0.05% spray. A total of 74 subjects were 
randomized to a 15-day treatment with 
betamethasone dipropionate 0.05% lotion, 15-day 
treatment with betamethasone dipropionate 0.05% 
spray, or 29-day treatment with betamethasone 
dipropionate 0.05% spray. At day 15, 22.7% of 
subjects in the 15-day betamethasone dipropionate 
lotion group and 20% in the 15-day betamethasone 
dipropionate spray group had abnormal ACTH 
stimulation tests (defined as plasma cortisol level of 
≤18 g/dl, 30 minutes after ACTH administration), 
suggesting HPA-axis suppression [19]. Plasma 
concentrations of betamethasone dipropionate 
were lower in subjects in the spray group compared 
with subjects in the lotion group despite greater 
amount of product used in the spray group, 
indicating less systemic absorption [19]. 
Triamcinolone acetonide 0.2% spray 
Triamcinolone acetonide 0.2% spray is a mid-
potency topical corticosteroid indicated for the 
inflammatory and pruritic relief of steroid-responsive 
dermatoses including eczema, psoriasis, atopic 
dermatitis, seborrheic dermatitis, and contact 
dermatitis [21, 22]. It can be applied to any area of the 
body, 3 to 4 times a day, but special care must be 
taken to avoid inhalation and eye contact [21]. 
Efficacy 
An open-label, single-center study evaluated the 
efficacy of triamcinolone acetonide 0.2% spray in 42 
adult subjects with mild-to-severe, steroid-
responsive inflammatory dermatoses. Most patients 
were instructed to apply medication 1 to 2 times a 
day but some were allowed to use the medication as 
needed up to 4 times a day. Clinical outcome was 
assessed using an Investigator and Patient Global 
Assessment Score (0=clear, 1=almost clear, 2=mild, 
3=moderate, 4=severe, 5=very severe), a Physician 
Assessment Improvement Score (0=complete 
clearing, 1=marked improvement [≥75% overall 
improvement], 2=moderate improvement [25-75% 
overall improvement], 3=mild improvement [≤25% 
overall improvement], 4=no response), and patient 
satisfaction was measured with a survey. GAS was 
measured at baseline and day 7, 14, 21, and 28, 
whereas patient satisfaction was assessed at day 28. 
At baseline, 83% of subjects had moderate-to-severe 
dermatoses whereas 17% had mild dermatoses. At 
day 14, 32% of subjects were completely clear or 
almost clear and no subject had severe dermatoses 
(no P value reported). After day 2, 64% of subjects 
were completely clear or almost clear. No subject 
reported severe dermatoses at day 14 (no P value 
reported). At day 28, 89% of subjects assessed their 
dermatoses as clear, almost clear, or mild on the 
patient global assessment scale (no P value 
reported). Mean scores for erythema, 
papules/vesicles, excoriations, pruritus, 
burning/stinging steadily decreased from baseline 
to day 28. Moderate improvement (25-75%) or 
complete clearing was observed using the 
physician’s assessment improvement scale after 7 
days of treatment in 32% of subjects (no P value 
reported). This increased to 64% of subjects after day 
28 of treatment (no P value reported). About 95% of 
subjects prefer triamcinolone spray over creams and 
ointments owing to descriptions of “no residue,” 
“easier to apply,” “not greasy,” “fast drying,” and “not 
sticky,” and 92.3% stated they would use 
triamcinolone spray again [22]. 
Safety and Tolerability 
Adverse reactions reported in decreasing order of 
occurrence include burning, irritation, dryness, 
Volume 25 Number 8| August 2019| 
25(8):3 
 
 
- 6 - 
Dermatology Online Journal  ||  Review 
folliculitis, hypertrichosis, acneiform eruptions, 
hypopigmentation, perioral dermatitis, allergic 
contact dermatitis, maceration of the skin, secondary 
infection, skin atrophy, striae, and miliaria. Such 
adverse reactions were infrequent and may increase 
with the use of occlusive dressing [21]. 
 
Discussion 
An increasing trend in prescribing nontraditional 
topical corticosteroid vehicles exists due to poor 
patient adherence and patients’ preferences for 
other vehicles [3]. Adherence to treatment is an 
important determinant of treatment success and 
overall clinical outcome [23]. Time consumption and 
poor cosmetic appearance associated with use of 
topical vehicles, including lotions and ointments, 
may contribute to poor adherence and treatment 
failure [24]. Spray vehicles may provide better clinical 
outcome for patients who prioritize factors such as 
ease of application and decreased messiness [23, 25]. 
Since patients’ preferences for topical vehicles are 
highly variable, healthcare providers could tailor 
treatment according to patients’ preferred vehicle of 
choice in order to attain good adherence [5]. 
Clobetasol propionate 0.05% spray formulation is an 
efficacious treatment for moderate-to-severe scalp 
and/or plaque psoriasis compared to placebo. 
Although there are a few comparative studies 
between different topical clobetasol propionate 
vehicles, topical sprays and other recent topical 
vehicle formulations have similar efficacy [23]. In a 
clinical setting, best outcomes may be achieved by 
selecting a vehicle based on patient preference [23]. 
Both calcipotriene 0.05% and betamethasone 
dipropionate 0.064% ointment with clobetasol 
propionate 0.05% spray were well tolerated and an 
efficacious therapy for moderate-to-severe plaque 
psoriasis. Clobetasol propionate 0.05% spray had 
greater improvement in efficacy compared to 
calcipotriene/betamethasone dipropionate 
ointment. Compared with clobetasol propionate 
0.05% spray, desoximetasone 0.25% spray has low 
allergenicity and low potential for adrenal 
suppression [16]. 
Although all topical corticosteroid sprays displayed 
similar clinical efficacy, superiority between each 
topical corticosteroid spray is difficult to compare 
since each clinical trial used different clinical 
outcome measurements. Therefore, whether to 
recommend one topical corticosteroid spray over 
another corticosteroid spray is difficult to determine. 
To help avoid such limitation, the International 
Dermatology Outcome Measure outlined standard 
clinical outcome measurements that may be 
implemented in all psoriasis clinical trials. Such 
measurements include the Physician Global 
Assessment, Body Surface Area, Psoriasis Area and 
Severity Index, Visual Analog Scale, Psoriasis 
Symptom Inventory, and Dermatology Life Quality 
Index [26-28]. The Harmonizing Outcome Measure 
for Eczema implemented similar standards in atopic 
dermatitis clinical trials [29]. Implementing all these 
clinical outcome measurements as a standard 
requirement in future studies can help compare 
results between all clinical trials in psoriasis and 
atopic dermatitis [26-29]. 
Adrenal suppression may be physiologic or 
pathologic. Physiologic adrenal suppression is the 
adrenal gland’s inability to release cortisol followed 
by quick normalization of hormone levels. 
Pathologic adrenal suppression is the prolonged or 
irreversible recovery of adrenal glands to produce 
cortisol [30]. Although betamethasone dipropionate 
0.05% spray caused adrenal suppression in 22.7% of 
subjects, a systematic review and risk analysis of 
topical corticosteroids found little evidence for 
pathologic or clinically significant physiologic 
adrenal suppression [19, 30]. Of 16 clinical trials, only 
one clinical trial reported pathologic adrenal 
suppression. Furthermore, of all subjects treated 
with class I to IV topical corticosteroids diagnosed 
with physiologic adrenal suppression, about 50% of 
those subjects reported normalized adrenal 
laboratory values within weeks of continued topical 
corticosteroid therapy. Topical corticosteroids 
appear to rarely cause symptomatic adrenal 
suppression [30]. 
Area of disease involvement may also help narrow a 
healthcare provider’s decision on choosing a vehicle 
of choice. For example, patients with scalp psoriasis 
may use a topical corticosteroid spray as it may be 
easier to use and less time-consuming. Subjects 
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strongly agreed that a spray pump applicator made 
it easier to apply the topical medication into their 
scalp [11]. However, newer topical corticosteroid 
vehicles including sprays and foams may be difficult 
to acquire owing to poor insurance coverage. 
Therefore, cost and availability act as barriers to 
patient adherence. Reducing copayments may 
improve patient adherence to topical therapy [31, 
32]. 
Clobetasol propionate 0.05% spray, desoximetasone 
0.25% spray, betamethasone dipropionate 0.05% 
spray and triamcinolone acetonide 0.02% spray are 
all effective treatments for psoriasis, atopic 
dermatitis, and other corticosteroid-sensitive 
dermatoses. Tailoring an appropriate vehicle to 
patient preference, severity, and area of disease 
involvement may improve patient adherence and 
overall clinical outcome [23]. 
 
Conclusion 
Topical corticosteroid sprays are effective and well-
tolerated treatments for steroid-responsive 
inflammatory dermatoses. Their ease of application 
make topical corticosteroid sprays an effective 
treatment alternative for patients that are not 
adherent to their prescribed medication. 
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Table 1: Efficacy of Topical Corticosteroid Sprays 
Authorship 
Study 
Design Intervention 
Subject 
Size Duration Result 
Jarrat et al. 
[7]. 
R, DB, 
PG, PC 
Clobetasol 
propionate 0.05% 
spray vs vehicle 
spray applied twice 
daily 
120 8 weeks 
ODS ≤2 at Week 2 or ≤1 at Week 4 
87% vs 17% at Week 2 (P<0.001) 
78% vs 3% at Week 4 (P<0.001) 
 
Clear/almost clear for psoriasis signs and 
symptoms at Week 4 
Plaque elevation (80% vs 15%, P≤0.001)  
Erythema (70% vs 5%, P≤0.001) 
Scaling (80% vs 15%, P≤0.001) 
Pruritus (80% vs 35%, P≤0.001) 
 
ODS ≤1 at Week 8 (4 weeks post-treatment) 
44% vs 4% (P≤0.001) 
Menter A. 
[8]. 
OL, O 
Clobetasol 
propionate 0.05% 
spray  
1254 4 weeks 
TPS ≤1 or 2-grade reduction 
43.6% at Week 2 (P<0.001) 
80% at Week 4 (P<0.001) 
 
GAI ≤1 
30.2% at Week 2 (No P-value reported) 
69.3% at Week 4 (P<0.001 vs Week 2) 
Feldman SR. 
[9]. OL, O 
Clobetasol 
propionate 0.05% 
spray twice daily as 
add-on treatment 
with antipsoriatic 
agent  
731 4 weeks 
TPS ≤ 1 or 2-grade reduction 
59% at Week 2 (P<0.001) 
80.3% at Week 4 (P<0.001) 
 
GAI ≤1 
26.5% at Week 2 (No P-value reported) 
62% at Week 4 (P<0.001) 
Menter A. 
[10]. R 
Clobetasol 
propionate 0.05% 
spray vs 
calcipotriene 
0.005% + 
betamethasone 
dipropionate 
0.064% ointment 
twice daily 
122 8 weeks 
ODS ≤ 1 
7% vs 12% at Week 1 (No P-value reported) 
41% vs 27% at Week 2 (No P-value reported) 
75% vs 45% at Week 4 (P=0.003) 
 
IGA ≤ 1 
20% vs 20% at Week 1 (No P-value reported) 
52% vs 33% at Week 2 (P=0.054) 
73% vs 65% at Week 4 (Difference did not reach 
statistical significance; no P-value reported) 
41% vs 24% at Week 8 (4 weeks post-treatment; 
no P-value reported) 
 
Mean change in PQLQ-12 from baseline 
-24.4 and 21.4 at Week 2 
-36.1 and -30.8 at Week 4 
-15.9 and -10.1 at Week 8 
Scores were reported as not statistically 
significant between groups (although no P-values 
were reported) 
 
Patient satisfaction survey (10-point scale) 
Ease of application: Median 10 vs 9 (P<0.001) 
Satisfaction: Median 9 vs 8  (P=0.03) 
Sofen et al. 
[11]. 
R, DB, 
PC 
Clobetasol 
propionate 0.05% 
spray vs vehicle 
81 2 or 4 weeks 
GSS ≤1 at Week 4 or GSS=0 at Week 2 
85% vs 13% at end of treatment (P<0.001) 
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spray applied twice 
daily 
Psoriasis individual sign scores at end of 
treatment (P<0.001 for differences in 
distribution between groups) 
Scaling: 96% vs 31% none or mild 
Erythema: 93% vs 36% none or mild 
Plaque elevation: 95% vs 48% none or mild 
 
Extent of scalp involvement index at end of 
treatment (P<0.001 for differences in 
distribution between groups) 
51% vs 3%: None 
39 vs 40%: <20% involvement  
10% vs 30%: 20-39% involvement 
0% vs 10 %: 40-59% involvement  
0% vs 13%: 60-79% involvement  
0% vs 5%: 80-100% involvement   
 
Pruritus severity score at end of treatment 
(P<0.001 for differences in distribution) 
68% vs 20% None 
29% vs 35% Mild 
2% vs 35% Moderate 
0% vs 10% Severe 
 
Scalpdex score (P<0.001 for differences 
between groups) 
Vehicle: 57.9 20.5 baseline vs 50.7 22.8 end of 
treatment (P=0.634) 
ITT: 55.0 21.0 baseline vs 30.0 22.0 end of 
treatment (P<0.001) 
Kircik et al. 
[15]. DB, PC 
Desoximetasone 
0.25% spray vs 
vehicle spray 
applied twice daily 
120 per 
study 28 days 
PGA ≤1 at Day 28 
Study 1: 31% vs 5% (P=0.003) 
Study 2: 53% vs 18% (P<0.0001) 
 
TLSS ≤1 for erythema, scaling, and plaque 
elevation at Day 28 
Study 1: 39% vs 7% (P<0.0001) 
Study 2: 53% vs 13% (P<0.0001) 
 
Mean change in TLSS from baseline 
Study 1: 4.73 3.08 vs 1.93 1.96 (P<0.0001) 
Study 2: 6.18 3.13 vs 3.022.97 (P<0.0001) 
 
Mean change in PGA from baseline 
Study 1: 1.14 0.9 vs 0.500.68 (P<0.0001) 
Study 2: 1.72 1.06 vs 0.850.94 (P<0.0001) 
 
Mean change in BSA from baseline 
Study 1: 2.24 3.79 vs 0.372.05 (P=0.0083) 
Study 2: 3.474.74 vs 1.27 4.23 (P=0.0083) 
Saleem et al. 
[16]. 
R, DB, 
PC 
Desoximetasone 
0.25% spray vs 
vehicle spray 
applied twice daily 
120 28 days 
PGA ≤1 at Day 28 
31% vs 5% (P=0.0003) 
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TLSS ≤1 for erythema, scaling, and plaque 
elevation at Day 28 
39% vs 7% (P<0.0001) 
Hoffman 
and Kircik 
[17]. 
OL 
Desoximetasone 
0.25% spray applied 
twice daily 
15 4 weeks 
IGA improvement from baseline of 3 
(moderate) 
Week 1: 7% IGA=0; 13% IGA=1; 80% IGA=2 
(P≤0.001) 
Week 2: 74% IGA ≤1; 27% IGA=2 (P≤0.001) 
Week4: 100% IGA ≤1 (P≤0.001) 
 
Pruritus at Week 4 from baseline of moderate 
40% mild, 60% none (P<0.002) 
 
Mean VAS percent change from baseline 
-56%, -74%, -91% at week 1, 2, and 4, respectively 
(P≤0.0007) 
Sidgiddi et 
al. [19]. 
PIII, R, 
DB, PC 
Betamethasone 
dipropionate 0.05% 
spray (n=174) vs 
betamethasone 
dipropionate 0.05% 
lotion (n=90) vs 
vehicle spray (n=87) 
applied twice daily 
394 29 days 
IGA ≤1 or 2-grade reduction at Day 15 
19% spray; 18.9% lotion 2.3% vehicle (P≤0.001 for 
spray vs vehicle) 
 
TSS reduction for erythema, scaling and 
plaque elevation 
12.1% in betamethasone group vs 2.3% in vehicle 
spray group with ≥50% reduction at 4 days 
(P=0.004) 
No statistically significance differences at Days 15 
and 29 (although no P-values was reported) 
Sidgiddi et 
al. [19]. 
R, OL, 
CC 
Betamethasone 
dipropionate 0.05% 
spray vs 
betamethasone 
dipropionate 0.05% 
lotion twice daily 
74 
15 or 29 
days 
Abnormal ACTH stimulation test 
15-day group: 20% spray, 22.7% lotion 
29-day spray group: 0% 
Fowler J 
[22]. OL 
Triamcinolone 
acetonide 0.2% 
spray 1-4 times daily 
42 28 days 
Investigator and Physician Global Assessment 
Score 
32% clear or almost clear at Day 14 (no P-value 
reported) 
89% clear or almost clear at Day 28 (no P-value 
reported) 
 
Physician Assessment of Improvement Score 
32% with 25 to 75% improvement or complete 
clearing at Day 7 (no P-value reported)  
64% with 25 to 75% improvement or complete 
clearing at Day 7 (no P-value reported) 
R-randomized; DB-double-blinded; PG-parallel-group; PC-placebo-controlled; ODS-Overall Disease Severity; OL-open-label; O-Observational; 
TLSS-Target Lesion Severity Scale; TPS-Target Plaque Severity; GAI-Global Assessment of Improvement; PQLQ-12- Patient Quality of Life 
Questionnaire; ITT-Intent-to-treat; GSS-Global Severity Score; PGA-Physician’s Global Assessment; VAS-Visual Analogue Scale; TSS-Total sign 
score; CC-Comparator-controlled 
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